Meanwhile, Metcash has
gained shareholder approval for the buy - out of its South African parent, 52 per cent shareholder, Metoz.
Not exact matches
The deal, assuming it
gains all necessary regulatory and
shareholder approvals, is expected to close in fiscal third quarter 2016.
The value of the deal for Genzyme's
shareholders is contingent on the success of alemtuzumab in treating MS; the first milestone is for the drug to
gain approval from the US Food and Drug Administration before the end of March 2014.